Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna AFS debt securities maturing in 1 to 5 years by Quarter
AFS debt securities maturing in 1 to 5 years — Fair value ($M) ($M)
Moderna AFS debt securities maturing in 1 to 5 years: $1,772M in Q2 2026, down 25.4% from a year earlier.
Latest, Q2 2026
1,772
Period ended Jun 30, 2026
Change on a year earlier
-25.4%
2,374 in Q2 2025
History
32 quarters
Since Q1 2018
Sources
30
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 5.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | AFS debt securities maturing in 1 to 5 years — Fair value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,772 | -25.4% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,251 | -6.9% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,336 | -6.3% | Form 10-Q (filed 2026-07-31) ↗ |
| Q3 2025 | Sep 30, 2025 | 2,143 | -8.2% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,374 | +2.1% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,418 | -33.5% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,494 | -46.7% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,335 | -55.7% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 2,326 | -61.9% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 3,638 | -51.1% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 4,677 | -43.8% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2023 | Sep 30, 2023 | 5,273 | -39.1% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 6,105 | -39.9% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 7,442 | -18.9% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 8,318 | +21.6% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 8,655 | +34.4% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 10,162 | +141.5% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 9,171 | +1,859.6% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 6,843 | +970.9% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2021 | Sep 30, 2021 | 6,442 | +830.9% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 4,207 | +1,085.4% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 468 | -6.9% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 639 | +299.4% | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 692 | +147.2% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 355 | -2.8% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 503 | +14.8% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 160 | -7.5% | Form 10-K (filed 2021-02-26) ↗ |
| Q3 2019 | Sep 30, 2019 | 280 | – | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 365 | – | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 438 | +153.0% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 173 | – | Form 10-K (filed 2020-02-27) ↗ |
| Q1 2018 | Mar 31, 2018 | 173 | – | Form 10-Q (filed 2019-05-09) ↗ |
Cite this data
StockData. (2026). Moderna AFS debt securities maturing in 1 to 5 years ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/afs-mat-1-5y-fv
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.